The allogeneic dilemma
- 6 August 2007
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 40 (12) , 1123-1128
Abstract
The place of allogeneic SCT in the management of multiple myeloma remains controversial. Although it may induce long-term clinical and molecular remissions, the very high transplant-related toxicity after a myeloablative preparative regimen has limited its role to younger patients as first-line treatment option. Even with this limited indication, toxic death rate related to infections and GVHD is considered too high and this strategy has been almost abandoned. Reduced intensity conditioning (RIC) regimens look promising, as the transplant-related mortality is low even with matched unrelated donors and can be considered for older patients up to the age of 65 years. However when used in patients with a high tumor burden or with chemo-resistant disease, the immunologic effect of the graft is not sufficient to avoid relapses. Therefore, RIC allotransplantation is currently used after tumor mass reduction with high-dose therapy followed by autologous SCT. A recently published Italian study shows that this strategy induces better event-free survival than double autologous SCT due to a reduced relapse rate. The questions raised by this encouraging result are discussed in this paper.Keywords
This publication has 42 references indexed in Scilit:
- A Comparison of Allografting with Autografting for Newly Diagnosed MyelomaNew England Journal of Medicine, 2007
- Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myelomaBlood, 2006
- Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myelomaBlood, 2006
- Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myelomaBone Marrow Transplantation, 2005
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myelomaBlood, 2002
- Autologous and allogeneic transplantation for multiple myeloma at a single centreBone Marrow Transplantation, 1997
- Graft-versus-myeloma effectThe Lancet, 1996
- Graft-versus-myeloma effect in two casesThe Lancet, 1996